Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2311-2315

  Pai Scherf, Lee H ^a   Villa, Jacy ^a   Pearson, Deborah ^a   Watson, Thelma ^a   Liu, Edison ^a   Willingham, Mark C ^b   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; MONOCLONAL ANTIBODY; PSEUDOMONAS EXOTOXIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; ESOPHAGUS CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADP RIBOSE TRANSFERASES; ADULT; ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ASPARTATE AMINOTRANSFERASES; BACTERIAL TOXINS; BREAST NEOPLASMS; ESOPHAGEAL NEOPLASMS; EXOTOXINS; FEMALE; HUMANS; IMMUNOTOXINS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; VIRULENCE FACTORS;

EID: 0032837077     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Slamon, D., Godolphim, W., Jones, L. A., Holt J. A., Wong, S. B., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER2/neu protooncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
2. Schneider, P. M., Hung, M. C., Chiocca, S. M., Manning, J., Zhao, X. Y., Fang, K., et al. Differential expression of the erbB2 gene in human small cell and non-small cell lung cancer. Cancer Res., 49: 4968-4971, 1989.
3. Park, J., Rhim, J. S., Park, S. C., Kimm, S. W., and Kraus, M. H. Amplification, overexpression and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res., 49: 6605-6609, 1989.
4. Press, M. F., Cordon-Cardo, C., and Slamon, D. J. Expression of the HER.-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5: 953-962, 1990.
5. Kasprzyk, P. G., Song, S. V., DiFiore, P. P., and King, C. R. Therapy of an animal model of human gastric cancer using a combination of anti-erbB2 monoclonal antibodies. Cancer Res., 52: 2771-2776, 1992.
6. Reiter, Y., Brinkmann, U., Jung, S-H., Pastan, I., and Lee, B. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide Stabilization of the Fv fragment. J. Biol. Chem., 269: 18327-18331, 1994.
7. Allured, V. S., Collier, R. J., Carroll, S. F., and McKay, D. B. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 angstrom resolution. Proc. Natl. Acad. Sci. USA, 83: 1320-1324, 1986.
8. Reiter, Y., Brinkmann, U., Kreitman, R., Jung, S-H., Lee, B., and Pastan, I. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry, 33: 5451-5459, 1994.
9. Reiter, Y., and Pastan, I. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin. Cancer Res., 2: 245-252, 1998.
10. Jain, R. K. Delivery of novel therapeutic agents in tumors: physiological Barriers and strategies. J. Natl. Cancer Inst., 8: 570-576, 1989.
11. Maloney, D. G., Grillo-Lopes, A. J., Bodkin, D, White, C. A., Liles, T. M., and Royston, I. IDEC-C2B8 (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90: 2188-2195, 1997.
12. Cobleigh, M. A., Vogel, C. L., Tripathy, N. J., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Paton, V., Shak, S., Lieberman, G., and Slamon, D. Efficacy and safety of Herceptin (humanized anti-Her2 antibody) as a single agent in 222 humans with Her2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., Abstract 376, 97a, 1998.
13. Slamon, D., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Baselga, J., and Norton, L. Addition of Herceptin (humanized anti-Her2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HEr2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled Phase III trial. Proc. Am. Soc. Clin. Oncol., Abstract 397, 98a, 1998.
14. Pai, L. H., and Pastan, I. Immunotoxin therapy for cancer. J. Am. Med. Assoc., 269: 78-81, 1993.
15. Kreitman, R. J., and Pastan, I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin. Cancer Biol., 6: 297-306, 1995.